Literature DB >> 8897888

Effect of morphine and naloxone on motor response of the human esophagus to swallowing and distension.

R Penagini1, A Picone, P A Bianchi.   

Abstract

The effect of morphine on esophageal motility has been little explored. In eight healthy volunteers, we studied the effect of intravenous morphine (100 micrograms/kg) followed 60 min later by intravenous naloxone (80 micrograms/kg) and of intravenous naloxone alone (80 micrograms/kg) on the esophageal motor response to swallowing and 30-s intraluminal distensions(4, 6, 8, and 10 ml) during two separate experiments. Morphine increased (P < 0.01) the velocity but did not alter the amplitude or duration of primary peristalsis, and it decreased the duration and magnitude of swallow-induced lower esophageal sphincter (LES) relaxation (P < 0.01). It also markedly increased contractile activity below the balloon at high distending volumes (P < 0.05) and decreased the magnitude of distension-induced LES relaxation (P < 0.05) but did not affect contractile activity above the balloon. All effects were reversed by naloxone. The latter alone did not influence the esophageal response to swallowing or distension. The conclusions are that 1) morphine exerts effects on the response of the human esophagus to swallowing and intraluminal distension that are consistent with an action at the level of the inhibitory neural pathways, 2) these effects occur through opioid receptors, and 3) endogenous opioids do not seem to control esophageal motility, at least through mu-receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897888     DOI: 10.1152/ajpgi.1996.271.4.G675

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

1.  Opiate-induced oesophageal dysmotility.

Authors:  R E Kraichely; A S Arora; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2009-12-08       Impact factor: 8.171

2.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 3.  Achalasia: It Is Not All Black and White.

Authors:  Santosh Sanagapalli; Rami Sweis
Journal:  Curr Gastroenterol Rep       Date:  2017-06

Review 4.  Esophagogastric Junction Outflow Obstruction: Current Approach to Diagnosis and Management.

Authors:  Thomas A Zikos; George Triadafilopoulos; John O Clarke
Journal:  Curr Gastroenterol Rep       Date:  2020-02-05

5.  Motility Patterns Following Esophageal Pharmacologic Provocation With Amyl Nitrite or Cholecystokinin During High-Resolution Manometry Distinguish Idiopathic vs Opioid-Induced Type 3 Achalasia.

Authors:  Arash Babaei; Sadaf Shad; Benson T Massey
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-13       Impact factor: 11.382

6.  Chronic daily opioid exposure is associated with dysphagia, esophageal outflow obstruction, and disordered peristalsis.

Authors:  Arash Babaei; Aniko Szabo; Sadaf Shad; Benson T Massey
Journal:  Neurogastroenterol Motil       Date:  2019-04-17       Impact factor: 3.598

Review 7.  Neuro-regulation of lower esophageal sphincter function as treatment for gastroesophageal reflux disease.

Authors:  Anupender Singh Sidhu; George Triadafilopoulos
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

Review 8.  Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.

Authors:  Marcello Tonini; Roberto De Giorgio; Fabrizio De Ponti
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Aging and intestinal motility: a review of factors that affect intestinal motility in the aged.

Authors:  Denis O'Mahony; Paula O'Leary; Eamonn M M Quigley
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Minor esophageal functional disorders: are they relevant?

Authors:  Ryan A Balko; Don C Codipilly; Karthik Ravi
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.